Search results
Results from the WOW.Com Content Network
Mycophenolate mofetil, a prodrug form of mycophenolic acid used in medicine. Mycophenolate mofetil is the morpholino ethyl ester of mycophenolic acid; the ester masks the carboxyl group. [42] Mycophenolate mofetil is reported to have a pKa values of 5.6 for the morpholino moiety and 8.5 for the phenolic group.
Although it is not commercialised as antibiotic due to its adverse effects, its modified compound (ester derivative) is an approved immunosuppressant drug in kidney, heart, and liver transplantations, and is marketed under the brands CellCept (mycophenolate mofetil; Roche) and Myfortic (mycophenolate sodium; Novartis). [8]
It is marketed by both Abbvie and Genentech USA, which is a member of the Roche Group. [14] AbbVie and Genentech are both commercializing the drug within the United States, but only AbbVie has rights to do so outside of the U.S. [20] According to Reuters 2016 Drugs to Watch, the 2020 forecast sales for venetoclax are US$1.48 billion.
Redoxon Double Action Vitamin C standard tablets Redoxon Vita Guard Ace+ Vitamin C standard tablets Redoxon is the brand name of the first artificially synthesized ascorbic acid ( vitamin C ). [ 1 ] Redoxon was first marketed to the general public by Roche in 1934, making it the first mass-manufactured synthetic vitamin in history. [ 2 ]
The tables below contain a sample list of benzodiazepines and benzodiazepine analogs that are commonly prescribed, with their basic pharmacological characteristics, such as half-life and equivalent doses to other benzodiazepines, also listed, along with their trade names and primary uses.
Roche said the disease affects around 20,000 people worldwide. The approval is based on a late-stage study in which PiaSky showed a 79.3% control in the destruction of red blood cells versus 79% ...
Nitazoxanide alone has shown preliminary evidence of efficacy in the treatment of chronic hepatitis B over a one-year course of therapy. [17] Nitazoxanide 500 mg twice daily resulted in a decrease in serum HBV DNA in all of 4 HBeAg-positive patients, with undetectable HBV DNA in 2 of 4 patients, loss of HBeAg in 3 patients, and loss of HBsAg in one patient.
Risdiplam, sold under the brand name Evrysdi, is a medication used to treat spinal muscular atrophy (SMA) [6] [9] and the first oral medication approved to treat this disease.